Adj TC + Herceptin Early Stage Breast Cancer
Completed
The purpose of this research study is to find out what effects (good and bad) docetaxel/cyclophosphamide (brand names: Taxotere and Cytoxan, or TC) plus trastuzumab (brand name: Herceptin, or H) has HER2+ breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
09/15/2016
Locations: Hematology Oncology Associates of IL, Chicago, Illinois +1 locations
Conditions: Breast Cancer
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Completed
This study will develop a national cord blood bank for siblings of patients with hemoglobinopathies and thalassemia.
Gender:
ALL
Ages:
Between 3 years and 14 years
Trial Updated:
07/28/2016
Locations: Children's Memorial Hospital, Chicago, Illinois
Conditions: Hematologic Diseases, Anemia, Sickle Cell, Beta-Thalassemia, Hematopoietic Stem Cell Transplantation
Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and rituximab w... Read More
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
07/15/2016
Locations: Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois +4 locations
Conditions: Lymphoma
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining rituximab with combination chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab with combination chemotherapy in treating patients who have previous... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/15/2016
Locations: Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois +5 locations
Conditions: Lymphoma
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating aggressive non-Hodgkin's lymphoma. PURPOSE: Randomized phase II trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have previously untreated aggressive stage II, stage III... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/12/2016
Locations: Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois +1 locations
Conditions: Lymphoma
Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have untreated acute lymphoblastic leukemia.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
07/01/2016
Locations: University of Illinois at Chicago Health Sciences Center, Chicago, Illinois +2 locations
Conditions: Leukemia
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Completed
RATIONALE: Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. The donated stem cells may also help destroy any remaining cancer cells (graft-versus-tumor effect). PURPOSE: This phase II trial is studying how well autologous peripheral stem cell transplant followed by donor peripheral stem cell transplant works in treating patients with multiple myeloma.
Gender:
ALL
Ages:
64 years and below
Trial Updated:
07/01/2016
Locations: University of Chicago Cancer Research Center, Chicago, Illinois
Conditions: Multiple Myeloma, Plasma Cell Neoplasm
Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of cyclophosphamide and filgrastim in treating patients with stage IV, relapsed, or refractory low-grade follicular non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/30/2016
Locations: University of Chicago Cancer Research Center, Chicago, Illinois
Conditions: Lymphoma
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
Unknown
The primary purpose of this study is to determine whether breast cancer tumors respond (as measured by pathologic complete response: the absence of microscopic evidence of invasive tumor cells in the breast) to combined chemotherapy of AC(doxorubicin and cyclophosphamide) followed by paclitaxel plus trastuzumab or lapatinib or both given before surgery to patients with HER2-positive breast cancer. Trastuzumab will also be given to all patients after surgery. The study will also evaluate the toxi... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/03/2016
Locations: Rush University Medical Center, Chicago, Illinois +6 locations
Conditions: Invasive Breast Cancer
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating childhood acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing different combination chemotherapy regimens to see how well they work in treating children with acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 9 years
Trial Updated:
02/19/2016
Locations: University of Chicago Cancer Research Center, Chicago, Illinois +3 locations
Conditions: Leukemia
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
Completed
This study is for individuals with lupus who have developed complications in their kidneys, or lupus nephritis. The study will determine whether adding the experimental medication abatacept to standard cyclophosphamide therapy is more effective in improving lupus nephritis than standard cyclophosphamide therapy by itself.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
01/15/2016
Locations: Rush University Medical Center, Chicago, Illinois +1 locations
Conditions: Lupus Nephritis, Lupus Erythematosus, Systemic
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving intrathecal and systemic combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system (CNS)... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
12/18/2015
Locations: Children's Memorial Hospital - Chicago, Chicago, Illinois
Conditions: Central Nervous System Tumor, Pediatric